General Information
Sanofi DM EFC12404
A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/lixisenatide fixed ratio combination to insulin glargine and to lixisenatide alone on top of metformin in patients with T2DM
| Protocol | EFC12404 |
|---|---|
| Identifier | EFC12404 Site Number 840-090 |
| UID | 63b1bad6-c0a0-498b-b3c1-3c09ff6ee057 |
| Status | Done - Archived |
| Phase | 3 |
| Category | Diabetes Type 2 |
| Launch Year | 2014 |
| NCT Number | - |
| Created | 2013-09-10 12:08 |
| Last Updated | 2013-09-10 12:08 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2014-09-16 | No |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2014-02-27 | No |
| PI Meeting Start | 2014-03-06 | No |
| PI Meeting End | 2014-03-07 | No |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2015-09-23 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Unger, Jeffrey | JUnger | No |
| Recruiter | - | No | |
| Coordinator | Barnett, Omar | OBarnett | No |
| Regulatory | - | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Sanofi-Aventis |
|---|---|
| Division | Sanofi-Aventis |
| Team | Sanofi-Aventis |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
